Latest News

Ixogel was granted QIDP Status by the FDA in September 2015 and is
working with the FDA on the Special Protocoll Assesment (SPA)


Ixodes carried out a phase III placebo controlled three stage design trial. 1371 patients were enrolled.

First stage was reached in 2Q2013. It demonstrated excellent safety for Ixogel. The trial was stopped since efficacy could not yet be proven with the endpoint based on clinical symptoms and serological titers.

However, a strong trend to prevent clinical symptoms of borreliosis was shown. As a first result, 8 symptoms of borreliosis were related to placebo treatment in contrast to zero symptoms for those receiving Ixogel.

Home i About us i Ixogel® i Lyme disease i Medical need i News i Team i Contact